ERAS

ERAS is undergoing High-Conviction Price Discovery driven by a structural re-rating of its pipeline, specifically the 'promising' preliminary Phase 1 data for its pan-RAS inhibitor (ERAS-0015). The stock has successfully absorbed a massive $258M equity offering priced at $10.00, trading +20% above this level, which signals immense institutional demand and validates the 'Perfect Stack' technical signal. In the current RISK_ON regime, capital is aggressively rotating into de-risked biotech assets with 'best-in-class' potential, ignoring the typical dampening effect of a secondary offering.